PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT2832778

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	PATENT SECURITY AGREEMENT (FIRST LIEN)

CONVEYING PARTY DATA

Name	Execution Date	
SYNARC INC.	03/10/2014	

RECEIVING PARTY DATA

Name:	CREDIT SUISSE AG, AS FIRST LIEN COLLATERAL AGENT
Street Address:	ELEVEN MADISON AVENUE, 23RD FLOOR
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10010

PROPERTY NUMBERS Total: 17

Property Type	Number
Patent Number:	6992280
Patent Number:	7157696
Patent Number:	7463758
Patent Number:	7561727
Patent Number:	8126240
Patent Number:	7844090
Patent Number:	8280126
Patent Number:	8315446
Patent Number:	8300910
Patent Number:	8218850
Patent Number:	8538102
Patent Number:	8285019
Application Number:	12069894
Application Number:	12450421
Application Number:	13701102
Application Number:	12936790
Application Number:	13377313

CORRESPONDENCE DATA

Fax Number: (714)755-8290

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via

TATELLE A

502786183 REEL: 032776 FRAME: 0798

US Mail.

 Phone:
 714-540-1235

 Email:
 ipdocket@lw.com

Correspondent Name: LATHAM & WATKINS LLP

Address Line 1: 650 TOWN CENTER DRIVE, SUITE 2000

Address Line 4: COSTA MESA, CALIFORNIA 92626

ATTORNEY DOCKET NUMBER:	030786-0602
NAME OF SUBMITTER:	ANNA T KWAN
SIGNATURE:	/atk/
DATE SIGNED:	04/28/2014

Total Attachments: 8

source=Project Ninja - 1L Patent Security Agreement (Execution)#page1.tif source=Project Ninja - 1L Patent Security Agreement (Execution)#page2.tif source=Project Ninja - 1L Patent Security Agreement (Execution)#page3.tif source=Project Ninja - 1L Patent Security Agreement (Execution)#page4.tif source=Project Ninja - 1L Patent Security Agreement (Execution)#page5.tif source=Project Ninja - 1L Patent Security Agreement (Execution)#page6.tif source=Project Ninja - 1L Patent Security Agreement (Execution)#page7.tif source=Project Ninja - 1L Patent Security Agreement (Execution)#page8.tif

Patent Security Agreement

PATENT SHORT FORM SECURITY AGREEMENT dated as of March 10, 2014, (this "Agreement"), among each of the undersigned grantors (individually, an "Grantor", and, collectively, the "Grantors") and CREDIT SUISSE AG, as First Lien Collateral Agent (in such capacity, together with its successors and assigns, the "First Lien Collateral Agent").

WHEREAS, Parent Borrower, Holdings (solely for purposes of Section 7.10 thereof), Synarc A/S, Center for Clinical and Basic Research A/S, the Lenders party thereto, Credit Suisse AG, as Administrative Agent (together with its successors and assigns, the "Administrative Agent"), and the other parties from time to time party thereto have entered into the First Lien Credit Agreement dated as of March 10, 2014 (as amended, amended and restated, extended, refinanced, replaced, supplemented or otherwise modified from time to time, the "Credit Agreement"). The Lenders have agreed to extend credit to the Borrowers subject to the terms and conditions set forth in the Credit Agreement conditioned upon, among other things, the execution and delivery of this Agreement.

WHEREAS, in connection with the Credit Agreement, the Grantor executed that First Lien Security Agreement (as amended, amended and restated, extended, refinanced, replaced, supplemented or otherwise modified from time to time, the "Security Agreement") dated as of March 10, 2014, among Synarc-BioCore Holdings, LLC, (the "Parent Borrower"), Synarc-BioCore Intermediate Holdings, LLC ("Holdings"), the other Subsidiary Parties named therein and CREDIT SUISSE AG, as First Lien Collateral Agent (together with its successors and assigns, the "First Lien Collateral Agent") pursuant to which the Grantor is required to execute and deliver this Agreement.

NOW, THEREFORE, in consideration of the foregoing and in order to induce the Lenders to make the Loans under the Credit Agreement and to induce the issuance of the Letters of Credit under the Credit Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Grantor hereby makes covenants and agrees with the First Lien Collateral Agent for the benefit of the Secured Parties as follows:

SECTION 1. <u>Terms</u>. Capitalized terms used in this Agreement and not otherwise defined herein have the meanings specified in the Security Agreement. The rules of construction specified in Section 1.04 of the Credit Agreement also apply to this Agreement.

SECTION 2. Grant of Security Interest. As security for the payment or performance, as the case may be, in full of the Obligations, including the Guaranty, the Grantor, pursuant to the Security Agreement, hereby assigns and pledges to the First Lien Collateral Agent, its successors and assigns, for the benefit of the Secured Creditors, and hereby grants to the First Lien Collateral Agent, its successors and assigns, for the benefit of the Secured Creditors, a security interest in, all right, title or interest in or to any and all of the following assets and properties now owned or at any time hereafter acquired by the Grantor or in which the Grantor now has or at any time in the future may acquire any right, title or interest (collectively, the "Patent Collateral"):

- (a) all letters patent of the United States, all registrations and recordings thereof, and all applications for letters patent of the United States, including registrations, recordings and pending applications in the USPTO or any similar offices in any other country, including those listed on Schedule I, and
- (b) all reissues, continuations, divisions, continuations-in-part, renewals or extensions thereof, and the inventions disclosed or claimed therein, including the right to make, use and/or sell the inventions disclosed or claimed therein, together with
- (c) any and all (i) proceeds, income, fees, royalties, damages, claims and payments now or hereafter due and/or payable with respect thereto, including damages and payments for past, present or future infringements or other violations thereof, (ii) rights to sue or otherwise recover for past, present or future infringements or other violations thereof and (iii) rights corresponding thereto throughout the world.

SECTION 3. <u>Purpose</u>. This Agreement has been executed and delivered by the Grantor for the purpose of recording the grant of security interest herein with the United States Patent and Trademark Office. The security interests granted to the First Lien Collateral Agent herein are granted in furtherance, and not in limitation of, the security interests granted to the First Lien Collateral Agent pursuant to the Security Agreement. Grantor hereby acknowledges and affirms that the rights and remedies of the First Lien Collateral Agent with respect to the Patent Collateral are more fully set forth in the Security Agreement, the terms and provisions of which are hereby incorporated herein by reference as if fully set forth herein. In the event of any conflict between the terms of this Agreement and the Security Agreement, the terms of the Security Agreement shall govern.

SECTION 4. <u>Recordation</u>. Each Assignor hereby authorizes and requests that the USPTO record this Agreement.

SECTION 5. <u>Applicable Law</u>. THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.

SECTION 6. <u>Counterparts</u>. This Agreement may be executed in multiple counterparts, each of which shall be an original and all of which collectively shall be one and the same agreement.

[Remainder of the page intentionally left blank]

IN WITNESS WHEREOF, each Grantor has caused this Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

BIOCLINICA, INC.

Name: Mark Weinstein

Title: President

SYNARC, INC.

Ву:_____

Name: Ted Kaminer

Title: Secretary & Treasurer

[First Lien Patent Security Agreement]

IN WITNESS WHEREOF, each Grantor has caused this Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

BIOCLINICA, INC.

В	y:y	i				 	 	 	
	W.Y.		- 1	V V 7	,	¥			

Name: Mark Weinstein

Title: President

SYNARC, INC.

Svame. Zed Kannher

Title: Secretary & Treasurer

[First Lien Patent Security Agreement]

CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH,

as First Lien Collateral Agent

By: Name:

Title: AUTHORIZED SIGNATORY

By:

Name: Title:

Sally Reyes

Authorized Signatory

[First Lien Patent Security Agreement]

Schedule I

<u>United States Patents and Pending Patent Applications</u>

<u>Title</u>	Patent No. (App. No.)	Issue Date (Fil. Date)	Owner	<u>Status</u>
Spine Phantom Simulating Cortical and Trabecular Bone for Calibration of Dual Energy X-Ray Bone Densitometers	6,302,582	10/16/2001	BioClinica, Inc. (as successor to Bio-Imaging Technologies, Inc.)	Granted
Variable Composition Phantom Simulating Varying Degrees of Body Fat for Dual Energy X-Ray Machine Calibration	6,315,447	11/13/2001	BioClinica, Inc. (as successor to Bio-Imaging Technologies, Inc.)	Granted
Test object for Calibration of Imaging Measurements of Mammalian Skeletal Joints	6992280 B2	1/31/2006	Synarc Inc.	Granted
Test object for Calibration of Imaging Measurements of Mammalian Skeletal Joints	7157696 B2	1/2/2007	Synarc Inc.	Granted
Method of Deriving a Quantitative Measure of a Degree of Calcification of an Aorta	7463758	12/9/2008	Synarc Inc.	Granted
Method of Deriving a Quantitative Measure of a Degree of Calcification of an Aorta	7561727	7/14/2009	Synarc Inc.	Granted

	D. ST	T To 2000			
Title	Patent No.	Issue Date (Fil.	Owner	<u>Status</u>	
	(App. No.)	Date)			
Vertebral Fracture	8126240	2/28/2012	Synarc Inc.	Granted	
Quantification					
Method of Deriving a	7844090	11/30/2010	Synarc Inc.	Granted	
Quantitative Measure of					
a Degree of					
Calcification of an					
Aorta					
Method of Deriving a	(12069894)	(02/13/2008)	Synarc Inc.	Pending	
Quantitative Measure of					
the Instability of					
Calcific Deposits of a					
Blood Vessel	000101	10101010			
Cartilage Curvature	8280126	10/2/2012	Synarc Inc.	Granted	
Breast Tissue Density	8315446	11/20/2012	Synarc Inc.	Granted	
Measure	0200010	10/20/2012	С Т	G . 1	
Pathology Indicating	8300910	10/30/2012	Synarc Inc.	Granted	
Measure					
Related to Cartilage Structure and					
Automatic					
Quantification Thereof					
Breast Tissue Density	8218850	7/10/2012	Synarc Inc.	Granted	
Measure	0210030	7710/2012	Synare me.	Granica	
Vertebral Fracture	(12450421)	(01/11/2010)	Synarc Inc.	Pending	
Prediction	(12 10 0 121)	(01/11/2010)		Tonumg	
Optimised Region of	8,538,102	9/17/2013	Synarc Inc.	Granted	
Interest					
Selection					
Breast Tissue Density	8285019	10/9/2012	Synarc Inc.	Granted	
Measure			-		
Computer based	(13701102)	(4/5/2013)	Synarc, Inc.	Pending	
analysis of MRI images					
Vertebral fracture	(12936790)	(12/27/2010)	Synarc, Inc.	Pending	
prediction					
Vertebral fracture	8126240	2/28/2012	Synarc, Inc.	Granted	
quantification					
Method of deriving a	7844090	11/30/2010	Synarc, Inc.	Granted	
quantitative measure of					
a degree of calcification					
of an aorta					

<u>Title</u>	Patent No. (App. No.)	Issue Date (Fil. Date)	Owner	Status
Method of deriving a quantitative measure of a degree of calcification of an aorta	7561727	7/14/2009	Synare, Inc.	Granted
Method of deriving a quantitative measure of a degree of calcification of an aorta	7463758	12/9/2008	Synarc, Inc.	Granted
Test object for calibration of imaging measurements of mammalian skeletal joints	7157696	1/2/2007	Synarc, Inc.	Granted
Test object for calibration of imaging measurements of mammalian skeletal joints	6992280	1/31/2006	Synarc, Inc.	Expired
Alignment of shapes of body parts from images	(13/377,313)	(6/20/2012)	Synarc, Inc.	Pending

PATENT REEL: 032776 FRAME: 0807

RECORDED: 04/28/2014